Menopause: Clinical Features, Diagnosis & Management

Menopause: Clinical Features, Diagnosis & Management
Evidence-Based Approach to Menopausal Hormone Therapy
Clinical Guidelines
Evidence-Based Medicine
Professor Mykhailo Medvediev
Based on International Clinical Practice Guidelines and Systematic Reviews
Introduction
Understanding Natural Menopause
Definition
Natural menopause is defined as the permanent cessation of menstrual periods, determined retrospectively after a woman has experienced 12 months of amenorrhea without any other obvious pathologic or physiologic cause.
It occurs at a median age of 51.4 years and reflects complete or near-complete ovarian follicular depletion, with resulting hypoestrogenemia and high FSH concentrations.
Key Characteristics
Median age: 51.4 years
95% occur between ages 45-55 years
Marked by ovarian follicular depletion
Elevated FSH levels
Low estradiol concentrations
Reference: Harlow SD, et al. J Clin Endocrinol Metab 2012;97:1159
STRAW Staging
Stages of Reproductive Aging Workshop (STRAW) System
The STRAW staging system is considered the gold standard for characterizing reproductive aging from the reproductive years through menopause. It includes criteria based upon bleeding patterns, endocrine findings, and symptoms.
01
Late Reproductive Years
Regular cycles with shortened follicular phase, rising FSH, preserved estradiol
02
Early Menopausal Transition
Change of ≥7 days in intermenstrual interval, variable FSH levels
03
Late Menopausal Transition
Skipped cycles, amenorrhea episodes, increasing anovulatory cycles
04
Postmenopause
12 months of amenorrhea, sustained elevated FSH (70-100 IU/L)
Reference: Harlow SD, et al. J Clin Endocrinol Metab 2012;97:1159
Endocrine Changes Across the Menopausal Transition
Hormonal Fluctuations
The menopausal transition is characterized by dramatic fluctuations in serum FSH and estradiol concentrations. A random serum sample may demonstrate high FSH and low estradiol consistent with menopause, but soon thereafter may return to normal premenopausal range.
Consequently, FSH measurements during the late menopausal transition are not routinely recommended due to their variability.
1
Inhibin B Decreases
Progressive decline in granulosa cell protein marker reflecting oocyte number
2
FSH Rises
Increase becomes sustained near FMP, reaching 70-100 IU/L range
3
Estradiol Fluctuates
Dramatic variations during transition, eventually declining postmenopause
Reference: Randolph JF Jr, et al. J Clin Endocrinol Metab 2011;96:746
Vasomotor Symptoms
Hot Flashes: The Hallmark Symptom
80%
Prevalence
Up to 80% of women experience hot flashes during menopausal transition
20-30%
Seek Treatment
Only 20-30% of affected women seek medical attention for symptoms
2-4 min
Duration
Typical hot flash lasts 2-4 minutes with profuse perspiration
Clinical Presentation
Sudden sensation of heat centered on upper chest and face
Rapidly becomes generalized
Associated with profuse perspiration
Occasionally palpitations
Sometimes followed by chills and shivering
Feeling of anxiety
Frequency & Timing
Hot flashes typically occur several times per day, ranging from 1-2 daily to as many as one per hour. They are particularly common at night (night sweats).
Symptoms are most common during late menopausal transition and early postmenopausal periods.
Reference: Gold EB, et al. Am J Public Health 2006;96:1226; Thurston RC, Joffe H. Obstet Gynecol Clin North Am 2011;38:489
Geographic Variability in Hot Flash Prevalence
There is considerable geographic variability in the prevalence of menopausal hot flashes. The reasons for this variation remain unclear, as smoking rates were similar across countries in comparative studies.
These differences may reflect genetic, dietary, cultural, or environmental factors that require further investigation.
Reference: Nappi RE, et al. Menopause 2021;28:875; Nappi RE, et al. Maturitas 2023;167:66
Duration
Duration of Vasomotor Symptoms
Long-Term Persistence
Contrary to earlier beliefs that vasomotor symptoms diminish within a few years, research demonstrates that symptoms can persist for as long as 20 years past the final menstrual period.
Duration may vary between racial and ethnic groups, with some populations experiencing longer symptom duration than others.
Impact on Quality of Life
Women with seven or more daily moderate to severe vasomotor symptoms report significant interference with:
Sleep (94%)
Mood (85%)
Concentration (84%)
Energy (77%)
Sexual activity (61%)
Clinical Significance
The more severe the vasomotor symptoms, the more daily activities are impacted, leading women to seek treatment to improve quality of life.
Reference: Avis NE, et al. JAMA Intern Med 2015;175:531; Williams RE, et al. Maturitas 2009;62:153
Impact of Menopausal Symptoms on Work
Work Absences
11% of women with moderate symptoms reported missing work in the preceding year (average of 3 days missed)
Economic Impact
Estimated annual $1.8 billion direct loss to the United States economy due to workdays missed
Severity Correlation
Women with severe symptoms were ~15 times more likely to have adverse work outcomes than those with mild symptoms
Hot flashes and other menopausal symptoms have a negative impact on work outcomes including absences, decreased hours, layoffs, firings, and job changes specifically due to menopause symptoms.
In a survey study of 4,440 menopausal women with moderate symptom scores, 480 (11%) reported missing work in the preceding year.
Reference: Faubion SS, et al. Mayo Clin Proc 2023;98:833
Mental Health
Depression and Menopausal Transition
Increased Risk
There is a significant increased risk of new-onset depression in women during the menopausal transition compared with their premenopausal years. The risk then decreases in the early postmenopause.
In a within-woman, eight-year longitudinal study, a diagnosis of depression was 2.5 times more likely to occur in the menopausal transition compared with when the woman was premenopausal (OR 2.50; 95% CI 1.25-5.02).
Risk Factors
Prior history of depression
Previous mood problems
Severe vasomotor symptoms
Sleep disturbances
Anxiety symptoms
Clinical Pearl
The association is most marked for women with a prior history of depression or mood problems.
Reference: Freeman EW, et al. Arch Gen Psychiatry 2006;63:375; Bromberger JT, et al. Am J Epidemiol 2003;158:347
Sleep Disturbances in Menopause
32-40%
Early Transition
Prevalence of difficulty sleeping in early menopausal transition
38-46%
Late Transition
Increased prevalence in late menopausal transition
53%
Sleep Disorders
Women with sleep disturbances had sleep apnea, restless legs, or both
Contributing Factors
Peri- and postmenopausal women experience sleep disturbances even in the absence of hot flashes. Multiple factors contribute:
Nighttime hot flashes (night sweats)
Anxiety and depression symptoms
Primary sleep disorders (sleep apnea, restless legs syndrome)
Hormonal fluctuations
In women reporting sleep disturbances, treating vasomotor symptoms may decrease sleep problems, but this may not resolve all issues as there are many other factors that can disturb sleep.
Reference: Freedman RR, Roehrs TA. Menopause 2007;14:826; Kravitz HM, et al. Menopause 2003;10:19
Cognitive Function
Cognitive Changes During Menopause
While biologic and epidemiologic evidence suggests that estrogen is important for cognitive function in women, the consequences of hormonal changes during the menopausal transition remain uncertain. Many women experience cognitive issues during the menopausal transition, but these symptoms are typically transient.
Reported Symptoms
Forgetfulness
Difficulties with word retrieval
"Brain fog"
Decreased concentration
Research Findings
In cross-sectional studies, women in late reproductive or perimenopausal years outperformed age-matched men in detailed memory tasks. These sex differences were attenuated in postmenopausal years.
Contributing Factors
SWAN study found that increases in anxiety and depression had independent, unfavorable effects on cognitive performance, but no decline in cognitive function was directly attributed to menopause.
Reference: Greendale GA, et al. Obstet Gynecol Clin North Am 2011;38:519; Greendale GA, et al. JAMA 2020;323:1495
GSM
Genitourinary Syndrome of Menopause (GSM)
Definition
GSM, formerly referred to as vulvovaginal atrophy, affects 50% of menopausal women. It is defined as a collection of symptoms and signs caused by hypoestrogenic and hypoandrogenic changes to the labia, clitoris, vagina, urethra, and bladder.
Clinical Impact
These symptoms develop later than other menopausal symptoms like hot flashes and may affect:
Sexual functioning
Emotional well-being
Body image
Interpersonal relations
Pathophysiology
GSM leads to decreased blood flow to the vagina and vulva, resulting in decreased vaginal lubrication and sexual dysfunction. Both estrogen and androgen deficiency may play a role.
Treatment Response
Symptoms related to GSM are exquisitely responsive to vaginal estrogen therapy.
Reference: Simon JA, et al. Menopause 2018;25:837; Palacios S, et al. Post Reprod Health 2020;26:32
Other Menopausal Symptoms
Joint Aches and Pain
Prevalence as high as 50-60% in cross-sectional studies. Association with menopausal status observed, with peri- and postmenopausal women experiencing more joint pain than premenopausal women.
Breast Pain
Common in early menopausal transition but begins to diminish in late transition. Likely due to fluctuations in serum estradiol concentrations.
Menstrual Migraines
Migraine headaches that cluster around onset of menstrual period. In many women, these worsen in frequency and intensity during menopausal transition.
While women who are obese or depressed are more likely to experience joint pain, there appears to be an association with menopausal status. In the WHI, women with joint pain or stiffness at baseline were more likely to get relief with hormone therapy than with placebo.
Reference: Szoeke CE, et al. Climacteric 2005;8:49; Dennerstein L, et al. Obstet Gynecol 2000;96:351
Cardiovascular
Long-Term Consequences: Cardiovascular Disease
Risk Increase After Menopause
The risk of cardiovascular disease increases after menopause, thought to be at least in part due to estrogen deficiency. This may be mediated by changes in cardiovascular risk factors such as lipid profiles that begin to change during perimenopause.
Lipid Profile Changes
Longitudinal data from over 2,500 subjects in the SWAN study showed:
6% increase in mean LDL (from 116 to 123 mg/dL)
No change in HDL levels
Possible decrease in protective effect of HDL
Clinical Significance
After adjusting for subject age, there was a small but significant increase in serum LDL during the menopausal transition from premenopausal years to early postmenopausal years.
Later SWAN ancillary study data suggested that the protective effect of HDL may decrease as women transition to menopause, adding another dimension to cardiovascular risk assessment.
Reference: Derby CA, et al. Am J Epidemiol 2009;169:1352; Woodard GA, et al. Menopause 2011;18:376
Long-Term Consequences: Bone Loss
1
Menopausal Transition
Bone loss begins during the menopausal transition with accelerated rates
2
Peak Loss Period
Highest annual rates occur 1 year before FMP through 2 years after
3
Postmenopause
Continued bone loss leading to increased osteoporosis risk
Mechanism
Estrogen deficiency leads to increased bone resorption and decreased bone formation, resulting in net bone loss. The annual rates of bone mineral density loss appear to be highest during the critical period surrounding the final menstrual period.
Clinical Implications
Understanding the timing of accelerated bone loss is crucial for:
Identifying women at risk
Timing of interventions
Prevention strategies
Fracture risk assessment
Reference: Neer RM, SWAN Investigators. Ann N Y Acad Sci 2010;1192:66
Body Composition
Changes in Body Composition
Fat Mass Increase
In early postmenopausal years, women who do not take estrogen therapy typically gain fat mass, particularly central adiposity
Lean Mass Loss
Concurrent loss of lean muscle mass occurs, contributing to metabolic changes and decreased strength
Weight Gain Pattern
Although women typically gain weight during midlife, it does not appear to be due to menopausal status or stage per se
Some, but not all, studies suggest that postmenopausal hormone therapy is associated with a decrease in central fat distribution. The relationship between menopause, hormone therapy, and body composition remains an area of active research.
Understanding these changes is important for counseling patients about realistic expectations and the role of lifestyle interventions.
Reference: Sternfeld B, et al. Am J Epidemiol 2004;160:912
Clinical Evaluation
Evaluation of Menopausal Women
General Approach
The evaluation depends on the patient's age (<40 years, 40-45 years, or over 45 years). For women of all ages, start with:
Assessment of menstrual cycle history
Menstrual calendar review
Detailed history of menopausal symptoms
Pelvic examination if indicated
Key Point
All women with symptoms of vaginal dryness, dyspareunia, or sexual dysfunction should have a pelvic examination to evaluate for vaginal atrophy.
01
History Taking
Comprehensive menstrual and symptom history with focus on vasomotor symptoms, mood changes, sleep disturbances
02
Physical Examination
Pelvic examination when indicated for genitourinary symptoms
03
Laboratory Testing
Selective use based on age and clinical presentation
Reference: Harlow SD, et al. J Clin Endocrinol Metab 2012;97:1159
Evaluation by Age Group: Women Over 45 Years
Women over age 45 years who present with characteristic menopausal signs and symptoms are more likely to be in the menopausal transition than to have a new endocrine disorder. Therefore, the diagnostic approach is streamlined.
Irregular Cycles + Symptoms
For women presenting with irregular menstrual cycles with menopausal symptoms (hot flashes, mood changes, sleep disturbance), no further diagnostic evaluation is suggested. They are highly likely to be in the menopausal transition.
Amenorrhea
For women with amenorrhea, pregnancy must always be considered. Obtain serum hCG in sexually active women not using reliable contraception.
Additional Features
For women with irregular cycles or amenorrhea who have features suggestive of hyperprolactinemia or thyroid disease, perform additional endocrine testing (prolactin and TSH).
Important Note on FSH Testing
Although serum FSH is often measured, it is not necessary to make the diagnosis and, if normal, may be misleading. Changes in menstrual bleeding patterns are a better predictor of menopausal stage than serum FSH concentrations.
Reference: Randolph JF Jr, et al. J Clin Endocrinol Metab 2006;91:3034
Evaluation: Ages 40-45 Years (Early Menopause)
Diagnostic Approach
For women between 40 and 45 years presenting with irregular menstrual cycles, with or without menopausal symptoms, possible diagnoses include early menopause or the menopausal transition.
We suggest the same endocrine evaluation as for any woman with oligo/amenorrhea to exclude other causes.
Required Laboratory Testing
Pregnancy: Serum hCG
Hyperprolactinemia: Serum prolactin
Thyroid dysfunction: Serum TSH
Optional: Serum FSH (variable results)
Although the presence of hot flashes with irregular menses strongly suggests the menopausal transition, it is prudent to look for other possible causes of oligo/amenorrhea in this age group.
Serum FSH concentrations are also typically measured but are not required to make the diagnosis of early menopause, and results are variable.
Reference: Harlow SD, et al. J Clin Endocrinol Metab 2012;97:1159
POI
Primary Ovarian Insufficiency: Age <40 Years
Definition
Women under age 40 years with irregular menses and menopausal symptoms should not be diagnosed with menopausal transition or menopause. They have primary ovarian insufficiency (POI).
Different Biology
The biology and natural history of POI are different from natural menopause and require different evaluation and management approaches.
Complete Evaluation
For women under 40 with irregular menses and menopausal symptoms, suggest complete evaluation for irregular menses and POI-specific workup.
If primary ovarian insufficiency is confirmed, further evaluation for this disorder should be performed, including assessment for autoimmune conditions, genetic causes, and other etiologies.
These women require long-term hormone replacement therapy until the average age of natural menopause to prevent premature cardiovascular disease, osteoporosis, and other health consequences.
Reference: Clinical manifestations and diagnosis of primary ovarian insufficiency. UpToDate 2024
Diagnosis of Menopausal Transition and Menopause
1
Women Over 45 Years
Diagnosis of menopausal transition based upon change in intermenstrual interval with or without menopausal symptoms. High serum FSH NOT required.
2
Menopause Diagnosis
Diagnosed as 12 months of amenorrhea in absence of other biologic or physiologic causes. High serum FSH NOT required.
3
Ages 40-45 Years
Same diagnosis criteria, but other causes of menstrual dysfunction must first be ruled out (normal hCG, prolactin, TSH).
4
Under Age 40
Should NOT be diagnosed with menopausal transition or menopause. They have primary ovarian insufficiency requiring different evaluation.
Reference: Harlow SD, et al. J Clin Endocrinol Metab 2012;97:1159
Differential Diagnosis
Differential Diagnosis of Menopausal Symptoms
Hyperthyroidism
Should always be considered in the differential diagnosis, as irregular menses, sweats (although different from typical hot flashes), and mood changes are all potential clinical manifestations.
Other Etiologies to Consider
Pregnancy - Always rule out in reproductive-age women
Hyperprolactinemia - Can cause amenorrhea and other symptoms
Hypothyroidism - May present with similar symptoms
Other endocrine disorders - Various hormonal imbalances
Atypical Hot Flashes
Atypical hot flashes and night sweats may be due to other disorders such as medications, carcinoid, pheochromocytoma, or underlying malignancy. These require specific evaluation.
Menstrual Cycle Changes
Other causes of menstrual irregularity should be systematically excluded before attributing symptoms solely to menopause, especially in younger women.
Reference: Overview of the clinical manifestations of hyperthyroidism in adults. UpToDate 2024
Hormone Therapy
Menopausal Hormone Therapy: Overview
Menopausal hormone therapy (MHT) is the broad term used to describe both unopposed estrogen use for women who have undergone hysterectomy and estrogen combined with progestogen therapy to prevent estrogen-associated endometrial hyperplasia in women with an intact uterus.
Primary Goal
Relief of vasomotor symptoms (hot flashes)
Secondary Benefits
Sleep disturbances, mood lability/depression, joint aches
Endometrial Protection
Progestogen required for women with intact uterus
Terminology
The term "hormone replacement therapy" (HRT) is now used only to describe hormone therapy for those with premature ovarian insufficiency or early menopause, not for natural menopause.
Current Approach
Our approach to MHT is consistent with clinical practice guidelines, including the 2022 Menopause Society position statement and Endocrine Society guidelines.
Reference: The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause 2022;29:767
Estrogen Preparations: Types and Routes
Oral Estrogen
17-beta estradiol (micronized), conjugated equine estrogens, esterified estrogens. Undergo first-pass hepatic metabolism affecting protein production.
Transdermal Estrogen
Patches containing 17-beta estradiol (0.014-0.1 mg/day). Avoids first-pass effect, lower VTE and stroke risk.
Topical Preparations
Gels, emulsions, lotions, and sprays. Various delivery systems and dosing options available.
Vaginal Preparations
Low-dose for GSM (4-10 mcg estradiol) or high-dose systemic rings (0.05-0.1 mg/day).
We prefer 17-beta estradiol over other types of estrogen as it is structurally identical (bioidentical) to the main product of the premenopausal ovary. For most women, we use transdermal rather than oral preparations due to lower cardiovascular risks.
Reference: Stuenkel CA, et al. J Clin Endocrinol Metab 2015;100:3975
Advantages of Transdermal Estrogen
Lower VTE Risk
Transdermal estrogen does not appear to increase the risk of venous thromboembolism, unlike oral preparations. Meta-analyses show no excess VTE risk even in women with prothrombotic mutations or high BMI.
Lower Stroke Risk
Low-dose transdermal estrogen (≤50 mcg patch) not associated with increased stroke risk. Population-based studies show rate ratio of 0.81 compared to nonusers.
Metabolic Advantages
Avoids first-pass hepatic metabolism, resulting in less impact on clotting factors, triglycerides, and binding globulins (SHBG, TBG, CBG).
Preferred for High-Risk Women
Particularly important for women with hypertriglyceridemia, active gallbladder disease, known thrombophilias, or migraine headaches.
There was an error generating this image
Clinical Recommendation
For most symptomatic women, we suggest transdermal 17-β-estradiol preparations over oral preparations.
Reference: Canonico M, et al. BMJ 2008;336:1227; Renoux C, et al. BMJ 2010;340:c2519
Estrogen Dosing: Standard and Low-Dose Regimens
Current Approach
The current approach is to start with lower doses and titrate up to relieve symptoms, rather than the historical "one-size-fits-all" approach.
Lower doses are associated with:
Less vaginal bleeding
Less breast tenderness
Fewer effects on coagulation
Possible lower risk of stroke and VTE
Dose Equivalents
Standard doses listed are approximately equivalent in efficacy for treating hot flashes. Lower doses (typically half the standard dose) are effective for many women.
The lowest available transdermal dose (0.014 mg) is approved for bone loss prevention and provides some benefit for hot flashes in approximately 50% of women.
Reference: Ettinger B. Am J Med 2005;118 Suppl 12B:74; Bachmann GA, et al. Obstet Gynecol 2007;110:771
Progestogens
Progestogen Therapy: Essential for Endometrial Protection
All women with an intact uterus need a progestogen added to their systemic estrogen to prevent endometrial hyperplasia, which can occur after as little as six months of unopposed estrogen. Women who have undergone hysterectomy should NOT receive progestogen.
Micronized Progesterone
First choice: 200 mg/day for 12 days/month (cyclic) or 100 mg daily (continuous). Bioidentical, metabolically neutral, no adverse cardiovascular effects.
Medroxyprogesterone Acetate
Most studied: 2.5 mg daily (continuous) or 5-10 mg/day (cyclic). Effective but associated with increased breast cancer and CHD risk in WHI.
Other Progestins
Norethindrone acetate, drospirenone, levonorgestrel (in combination products or IUD). Various options for women intolerant to standard progestogens.
Our first choice is oral natural micronized progesterone as it is structurally identical (bioidentical) to progesterone secreted by the human ovary and has advantages over synthetic progestins in terms of cardiovascular and breast cancer risk profiles.
Reference: Stute P, et al. Climacteric 2016;19:316; Stanczyk FZ, et al. Endocr Rev 2013;34:171
Progestogen Administration: Frequency and Regimens
1
Cyclic Regimen
Progestogen given 12-14 days per month. Results in monthly withdrawal bleeding. Mimics natural luteal phase.
2
Continuous Regimen
Progestogen given daily. Goal is amenorrhea. May have irregular bleeding initially, especially if <3 years postmenopausal.
3
Quarterly Regimens
NOT recommended. Progestogen every 3 months may not provide adequate endometrial protection.
Cyclic vs Continuous
Women taking standard doses of estrogen require monthly progestogens. Cyclic regimens almost always result in monthly withdrawal bleeding. Continuous regimens aim for amenorrhea but may have irregular bleeding initially.
Timing Considerations
Women more than 3 years postmenopausal are less likely to have breakthrough bleeding during the first year of continuous therapy compared with women less than 2 years postmenopausal (78% vs 65% amenorrhea rates).
Reference: Writing Group for PEPI Trial. JAMA 1996;275:370; Archer DF, et al. Menopause Study Group. Obstet Gynecol 1994;84:987
Managing Progestogen Intolerance
Some women experience mood symptoms and bloating with progestogens, most commonly with cyclic regimens. In some cases, individuals are unable to tolerate either cyclic or continuous progestogen administration.
Vaginal Progesterone
Vaginal administration of micronized progesterone capsules is easier to tolerate for some women. However, endometrial protection is less well established.
Levonorgestrel IUD
Off-label use of levonorgestrel-releasing IUD. Low-dose options (14 or 17.5 mcg) available. Provides high intrauterine but low systemic concentrations.
CEE/Bazedoxifene
Combination of conjugated estrogen with bazedoxifene (SERM). SERM prevents endometrial hyperplasia, eliminating need for progestin. Increased VTE risk.
Clinical Approach
For women unable to tolerate oral progestogens, we may consider switching to continuous regimen first. If still intolerant, alternative options include vaginal progesterone or levonorgestrel IUD (off-label).
Reference: Stanczyk FZ, et al. Endocr Rev 2013;34:171
Patient Selection
Is My Patient a Candidate for MHT?
Clinical Indications
Consider MHT for healthy, symptomatic women who are:
Within 10 years of menopause OR
Younger than age 60 years
Have moderate to severe vasomotor symptoms
Symptoms impact quality of life, sleep, or function
No contraindications to MHT
Contraindications
History of breast cancer
Coronary heart disease
Previous VTE or stroke
Active liver disease
Unexplained vaginal bleeding
High-risk endometrial cancer
Transient ischemic attack
Important
Calculate cardiovascular and breast cancer risks before initiating MHT.
For women at moderate CVD risk (5-10% 10-year risk), we suggest transdermal rather than oral estrogen. For women at high risk (>10% 10-year risk) for CVD or moderate-high risk for breast cancer, we suggest nonhormonal therapies.
Reference: Stuenkel CA, et al. J Clin Endocrinol Metab 2015;100:3975
Risk-Benefit Profile: Women Ages 50-59 Years
The absolute risk of complications for healthy, young postmenopausal women taking MHT is very low. Data are based on five years of hormone use in women starting treatment between ages 50-59 years.
+2.5
CHD (EPT)
Additional cases per 1000 women per 5 years
+3
Breast Cancer (EPT)
Additional cases per 1000 women per 5 years
+3
PE (EPT)
Additional cases per 1000 women per 5 years
-5
All-Cause Mortality
Fewer deaths per 1000 women per 5 years
Estrogen-Alone Therapy
CHD: 5.5 fewer cases
Breast cancer: 2.5 fewer cases
Stroke: 0.5 fewer cases
PE: 1.5 additional cases
Hip fracture: 1.5 fewer cases
All-cause mortality: 5.5 fewer events
Key Points
The overall risks of MHT in younger postmenopausal women are considerably lower than for older women. The major explanation is the lower baseline risk of CHD, stroke, VTE, and breast cancer in younger women.
Reference: Santen RJ, et al. J Clin Endocrinol Metab 2010;95:s1; Manson JE, et al. JAMA 2013;310:1353
Cardiovascular
MHT and Coronary Heart Disease
Older Women
WHI showed increased CHD risk with combined EPT (HR 1.23). No effect with unopposed estrogen (HR 0.95).
Younger Women
Women <10 years since menopause or ages 50-59 had no excess risk or possible reduction in risk.
Timing Hypothesis
Timing of treatment initiation affects CHD risk. Early initiation may be cardioprotective.
Current Recommendation
MHT not recommended for primary or secondary prevention of CHD, but safe for symptom relief in appropriate candidates.
Data from coronary angiographic studies, WHI coronary artery calcification study, and meta-analyses all suggest that timing of treatment initiation affects the risk of CHD. The KEEPS and ELITE trials in younger postmenopausal women showed no adverse cardiovascular effects.
Reference: Rossouw JE, et al. JAMA 2007;297:1465; Manson JE, et al. JAMA 2013;310:1353
MHT and Stroke Risk
Oral Estrogen
Clinical trial data suggest that oral estrogen increases stroke risk. In the WHI, a 31% increase in stroke risk was seen with combined CEE-MPA compared with placebo (HR 1.31, 95% CI 1.02-1.68).
The increase in risk is for ischemic but not hemorrhagic stroke. Excess risk was seen in all age groups but absolute risk is low in younger women.
For women ages 50-59 years: 0.15 vs 0.13 cases per 100 women per year for MHT and placebo.
Transdermal Estrogen
Low-dose transdermal estrogen therapy (≤50 mcg patch) does not appear to increase the risk of stroke in postmenopausal women.
Population-based case-control study: rate ratio 0.81 (95% CI 0.62-1.05) for low-dose transdermal estrogen vs nonusers.
Clinical Implication
Because baseline stroke risks are lower in younger postmenopausal women, the calculated absolute risk for women ages 50-59 years is very low, even with oral estrogen.
Reference: Wassertheil-Smoller S, et al. JAMA 2003;289:2673; Renoux C, et al. BMJ 2010;340:c2519
MHT and Venous Thromboembolism
5/1000
EPT (Ages 50-59)
Additional VTE cases per 1000 women over 5 years with combined estrogen-progestin
2/1000
ET (Ages 50-59)
Additional VTE cases per 1000 women over 5 years with estrogen alone
0
Transdermal
No excess VTE risk observed with transdermal estrogen in meta-analyses
Oral Estrogen Risk
Oral estrogen increases the risk of VTE. However, in women ages 50-59 years, the absolute risk is lower than in older postmenopausal women due to lower baseline VTE risk.
The WHI estimates of excess VTE risk overall (all age groups) were 9 and 4 per 1000 over five years for combined EPT and ET, respectively.
Transdermal Advantage
The risk of VTE appears to be lower with transdermal compared with oral estrogen preparations. Meta-analysis showed no excess risk of VTE with transdermal estrogen (OR 1.2, 95% CI 0.1-1.7).
No excess risk even in women with prothrombotic mutations or high BMI.
Reference: Cushman M, et al. JAMA 2004;292:1573; Canonico M, et al. BMJ 2008;336:1227
Breast Cancer
MHT and Breast Cancer Risk
In the WHI overall study population, combined CEE-MPA use increased the risk of breast cancer. However, the absolute risk with typical duration of use in women ages 50-59 years is very low: 3 additional cases per 1000 women over 5 years (therefore <1 per 1000/year).
Combined EPT
Absolute excess risk of 9 cases per 10,000 person-years overall (HR 1.24, 95% CI 1.01-1.53). For ages 50-59: 3 additional cases per 1000 over 5 years.
Unopposed Estrogen
WHI showed REDUCED risk with CEE alone. For ages 50-59: 2.5 fewer cases per 1000 over 5 years. Longer observational studies show small increase.
Type of Progestogen
Current regimens use micronized progesterone (preferred) rather than MPA. Limited data suggest natural progesterone may not increase breast cancer risk.
The magnitude of this risk is similar to reported risks in women with obesity and low physical activity. There does not appear to be an additive effect of hormone therapy with age or underlying breast cancer risk.
Reference: Manson JE, et al. JAMA 2013;310:1353; Anderson GL, et al. JAMA 2004;291:1701
MHT and Other Cancers
Ovarian Cancer
Very low absolute risk. WHI showed nonsignificant increase with EPT (HR 1.6, 95% CI 0.8-3.2). Excess risk ~0.75 cases per 1000 women over 5 years. Should not affect decision to take MHT for symptoms.
Endometrial Cancer
Unopposed systemic estrogen increases risk of endometrial hyperplasia and cancer. Risk largely abolished by concurrent progestogen therapy (cyclic or continuous). No significant difference in WHI EPT trial (HR 0.81, 95% CI 0.48-1.36).
Colorectal Cancer
Initial WHI data suggested decrease with combined EPT but no effect with estrogen alone. Subsequent analysis with 23 years follow-up showed similar risks in EPT, ET, and placebo groups.
Lung Cancer
Women on combined EPT who developed non-small cell lung cancer had significantly shorter survival compared with placebo. No increase in incidence, but worse outcomes.
All women with an intact uterus taking systemic estrogen from any route (oral, transdermal patch, vaginal ring) must receive concurrent progestogen to prevent endometrial hyperplasia and carcinoma.
Reference: Anderson GL, et al. JAMA 2003;290:1739; Chlebowski RT, et al. Lancet 2009;374:1243
MHT and Mortality
Overall Findings
Available data suggest that MHT is not associated with an increase in mortality rates when compared with placebo. Younger menopausal women (ages 50-59) may actually have a reduction in all-cause mortality with MHT.
The best available data come from an 18-year follow-up report from the WHI trials.
27%
Overall Mortality
Similar all-cause mortality (~27%) in women taking MHT or placebo over 18 years
0.61
Ages 50-59 (Intervention)
Hazard ratio during intervention phase (95% CI 0.43-0.87) - significant reduction
0.87
Ages 50-59 (18 years)
Hazard ratio at 18 years follow-up (95% CI 0.76-1.0) - trend toward reduction
Cardiovascular and cancer (including breast cancer) mortality rates were similar for MHT and placebo. When analyzed by 10-year age groups, MHT reduced all-cause mortality in women ages 50-59 years during the intervention phase.
Meta-analysis of 19 randomized trials in younger postmenopausal women showed MHT reduced mortality by 27% (RR 0.73, 95% CI 0.52-0.96).
Reference: Manson JE, et al. JAMA 2017;318:927; Salpeter SR, et al. Cochrane Database Syst Rev 2004;CD001018
Bone Health
MHT and Osteoporotic Fracture Prevention
In the WHI trial, both unopposed estrogen and combined estrogen-progestin treatment significantly reduced fracture risk. However, MHT is no longer recommended solely for prevention of osteoporosis.
Hip Fracture Reduction
For women ages 50-59: 4.9-5.9 fewer fractures per 1000 women over 5 years
Vertebral Fracture
Significant reduction in vertebral fractures with both EPT and ET
All Fractures
Overall decrease in all osteoporotic fractures in both estrogen and combined groups
Mechanism
Estrogen reduces bone resorption and maintains bone mineral density. The protective effect on bone is a beneficial side effect for women taking MHT for vasomotor symptoms.
Clinical Implications
While bone protection is a benefit of MHT, it should not be the primary indication for therapy. Other osteoporosis treatments are available for women who need bone protection but not symptom relief.
Reference: Cauley JA, et al. JAMA 2003;290:1729; Santen RJ, et al. J Clin Endocrinol Metab 2010;95:s1
MHT and Cognitive Function/Dementia
Current Evidence
There is limited epidemiologic support for the hypothesis that estrogen preserves overall cognitive function in women. Meta-analyses of epidemiologic data and randomized trials have shown no benefit for prevention of dementia and no evidence of accelerated cognitive decline.
It is possible that there are domain-specific cognitive benefits (such as verbal memory) with MHT in younger postmenopausal women, but definitive evidence is lacking.
WHI Findings
In the WHI, both unopposed estrogen and combined estrogen-progestin therapy had no global cognitive benefits in older postmenopausal women without dementia.
Clinical Recommendation
MHT is not recommended for preservation of cognitive function or prevention of dementia.
Younger Women
Some evidence suggests domain-specific benefits in younger postmenopausal women, but more research is needed.
Older Women
No cognitive benefits demonstrated in older postmenopausal women. Possible increased risk of dementia with initiation after age 65.
Timing Hypothesis
Critical window hypothesis suggests timing of initiation may be important, but clinical trials have not confirmed benefits.
Reference: Hogervorst E, et al. Cochrane Database Syst Rev 2009;CD003122; Shumaker SA, et al. JAMA 2003;289:2651
Other Effects
MHT: Other Potential Benefits and Risks
Gallbladder Disease
Increased risk with oral estrogen. WHI showed 9.6-14.2 additional cases of cholecystitis per 1000 women over 5 years. Transdermal may have lower risk.
Type 2 Diabetes
MHT appears to reduce risk of type 2 diabetes. WHI showed 11 fewer cases per 1000 over 5 years. Effect insufficient to recommend MHT as diabetes prevention strategy.
Urinary Incontinence
Oral MHT worsens incontinence. Should not be prescribed for this indication. Extremely low-dose transdermal (0.014 mg/day) does not appear to increase risk.
Asthma
May be associated with onset of asthma. Nurses' Health Study showed RR 1.5 for new-onset asthma. Risk appears dose-related. Not contraindicated but monitor for worsening.
MHT has various effects on multiple organ systems. While some effects are beneficial (diabetes risk reduction), others are adverse (gallbladder disease, urinary incontinence). These should be considered in the overall risk-benefit assessment for individual patients.
Reference: Cirillo DJ, et al. Obstet Gynecol 2005;105:921; Margolis KL, et al. Diabetes Care 2004;27:2585
Duration of MHT Use
01
Standard Recommendation
Standard recommendation is 3-5 years duration, not beyond age 60 years. However, individualized approach is appropriate.
02
Extended Use
Extended use (beyond age 60 or >5 years) may be reasonable when benefits of symptom relief outweigh risks in carefully selected women.
03
Reassessment
Regular reassessment of need for continued therapy. Over 40% of women ages 60-65 have persistent hot flashes affecting quality of life.
04
Stopping Therapy
When stopping, consider tapering over 3-6 months or longer. May add nonhormonal therapy during taper to minimize recurrent symptoms.
Both The Menopause Society and ACOG agree that use of MHT should be individualized and not discontinued solely based upon patient age. They suggest that extended use may be reasonable when clinician and patient agree that benefits outweigh risks.
Reference: The 2022 Hormone Therapy Position Statement. Menopause 2022;29:767
Tapering and Stopping MHT
Approaches to Stopping
Data regarding abrupt cessation versus tapering are conflicting. Some women have no trouble stopping estrogen abruptly, while others experience significant return of symptoms.
In WHI, women who abruptly discontinued MHT were significantly more likely to develop moderate to severe symptoms compared to placebo group (56% vs 22% in those with baseline symptoms).
Tapering Methods
Oral preparations: Decrease by one pill per week every few weeks (6 pills/week for 2-4 weeks, then 5 pills/week, etc.)
Transdermal: Gradual dose reduction using lower-dose patches over 3-6 months or longer if needed.
Adjunct therapy: Start nonhormonal therapy (SSRI or gabapentin) during taper.
1
Initial Taper
First attempt at tapering, typically 3-6 months duration
2
Assess Response
Monitor for recurrent symptoms, adjust taper speed as needed
3
Extended Taper
If severe recurrent symptoms, try slower taper over 1 year
4
Resume if Needed
May resume MHT at lower dose if symptoms persist and significantly impact quality of life
Reference: Ockene JK, et al. Obstet Gynecol 2005;105:267
Special Populations
MHT in Special Populations: Primary Ovarian Insufficiency
Data from the WHI should NOT be extrapolated to women with primary ovarian insufficiency (POI, menopause before age 40) or early menopause (ages 40-45). These women require different management.
Hormone Therapy Indication
MHT is started at a younger age and should be continued until the average age of menopause (approximately age 50-51 years) to prevent premature health consequences.
Health Risks Without Treatment
Without hormone therapy, women with POI have increased risks of premature bone loss, coronary heart disease, stroke, and dementia.
Higher Doses Often Needed
Women with POI often require higher estrogen doses than typical menopausal women (e.g., 2 mg oral estradiol or 0.1 mg transdermal) for first 2-3 years.
At age 50-51 years, if hormone therapy is stopped and menopausal symptoms are moderate to severe, the same discussion of potential risks and benefits of MHT should take place as for women with natural menopause.
In otherwise healthy women with POI, we continue their MHT until the average age of menopause. This is considered hormone replacement therapy (HRT) rather than menopausal hormone therapy (MHT).
Reference: Management of primary ovarian insufficiency. UpToDate 2024
MHT in Breast Cancer Survivors
Contraindication
Although women with breast cancer often experience early menopause due to adjuvant chemotherapy and may have vasomotor symptoms, MHT should NOT be prescribed.
Evidence Base
The epidemiologic data and clinical trial data have been inconsistent, but the increased risk of breast cancer recurrence with estrogen in the HABITS trial is of great concern.
In HABITS, women with breast cancer history taking MHT had significantly increased recurrence risk compared to those not taking hormones.
Alternative Approaches
Nonhormonal therapies for hot flashes (SSRIs, SNRIs, gabapentin, fezolinetant)
Vaginal estrogen for GSM (very low systemic absorption)
Lifestyle modifications
Cognitive behavioral therapy
Strong Recommendation
We do NOT recommend estrogen for women with a personal history of breast cancer. Other established means of controlling symptoms or preventing osteoporosis should be utilized.
Reference: Holmberg L, et al. Lancet 2008;371:319
MHT in Women with Migraines
Not a Contraindication
Migraine headaches (with or without aura) are not considered to be a contraindication to MHT. For women with hot flashes and estrogen-associated migraines, estrogen therapy often improves both symptoms.
Preferred Regimen
We suggest continuous transdermal hormone regimens (as opposed to cyclic regimens) to avoid triggering estrogen-withdrawal headaches. Low-dose transdermal estradiol (≤0.025-0.05 mg) preferred.
Stroke Risk Considerations
The effect of MHT on stroke risk in postmenopausal women with migraines is not well studied. However, low doses of transdermal estradiol have not been associated with excess stroke risk in healthy women.
Estrogen-associated migraines typically worsen during perimenopause due to hormonal fluctuations. Continuous estrogen therapy can stabilize hormone levels and reduce migraine frequency.
The topics of menopause, hormone therapy, and migraine are complex and require individualized assessment and management.
Reference: Estrogen-associated migraine headache, including menstrual migraine. UpToDate 2024
Nonhormonal Options
Nonhormonal Therapies for Menopausal Symptoms
There are several nonhormonal options for treating hot flashes, which are appropriate for women who have contraindications to MHT, prefer nonhormonal therapy, or have persistent symptoms after stopping MHT.
SSRIs/SNRIs
Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors. Modest efficacy for hot flashes. Examples: paroxetine, venlafaxine, escitalopram.
Gabapentin
Anticonvulsant medication effective for hot flashes. Typical dose 300-900 mg/day. Side effects include dizziness and sedation.
Fezolinetant
Neurokinin 3 receptor antagonist. New FDA-approved nonhormonal option specifically for menopausal hot flashes. Effective and well-tolerated.
Efficacy Comparison
Nonhormonal therapies are less effective than MHT for hot flashes but provide meaningful benefit for many women. SSRIs/SNRIs reduce hot flash frequency by approximately 50%, compared to 75-80% reduction with MHT.
Patient Selection
Consider nonhormonal therapies for women with:
Contraindications to MHT
Personal preference for nonhormonal treatment
Breast cancer history
High cardiovascular risk
Reference: Menopausal hot flashes. UpToDate 2024
Lifestyle Modifications and Complementary Approaches
Cognitive Behavioral Therapy
CBT has shown efficacy for managing hot flashes and improving quality of life. Focuses on changing thoughts and behaviors related to symptoms.
Mindfulness and Meditation
Mindfulness-based stress reduction may help with symptom management and overall well-being during menopausal transition.
Exercise
Regular physical activity may help with mood, sleep, weight management, and overall health. Evidence for hot flash reduction is mixed.
Dietary Modifications
Avoiding triggers (spicy foods, caffeine, alcohol), maintaining healthy weight. Soy isoflavones have modest effects at best.
Acupuncture
Some evidence for modest benefit, though studies show mixed results. May be worth trying for women seeking complementary approaches.
While lifestyle modifications and complementary approaches may provide some benefit, evidence for efficacy is limited for most interventions. They are best used as adjuncts to other therapies rather than sole treatments for moderate to severe symptoms.
Reference: Nonhormonal management of menopause-associated vasomotor symptoms. UpToDate 2024
Clinical Practice
Practical Approach to Initiating MHT
Step 1: Assessment
Comprehensive evaluation including age, years since menopause, symptom severity, medical history, contraindications, and risk factors.
Step 2: Risk Calculation
Calculate cardiovascular risk (10-year ACC/AHA) and breast cancer risk (Gail model or similar). Determine if patient is appropriate candidate.
Step 3: Shared Decision Making
Discuss risks and benefits specific to patient's age and risk profile. Review alternatives. Ensure informed consent.
Step 4: Choose Regimen
Select estrogen type and route (prefer transdermal 17β-estradiol). Add progestogen if uterus intact (prefer micronized progesterone). Start low dose.
Step 5: Follow-Up
Assess symptom relief at 4-6 weeks. Titrate dose if needed. Monitor for side effects. Annual reassessment of continued need.
Reference: Stuenkel CA, et al. J Clin Endocrinol Metab 2015;100:3975
Monitoring Women on MHT
Dose Adjustments
Start with lower estrogen doses and titrate up to relieve symptoms. Hot flash relief often occurs within 3-4 weeks. If persistent symptoms after that time, increase estrogen dose.
For women with severe symptoms, start with higher dose for rapid relief, then consider tapering to lower maintenance dose.
Endometrial Monitoring
Vaginal bleeding in women receiving hormone therapy may require endometrial evaluation:
Irregular bleeding before starting therapy: endometrial biopsy
Continuous combined therapy: follow bleeding for 6 months, then biopsy if persistent
Cyclic therapy: regular withdrawal bleeding expected
Mammography
Routine mammograms and breast examinations recommended. In WHI, risk of breast cancer with EPT did not increase until fourth year, but abnormal mammograms were more common.
Cardiovascular Monitoring
Monitor blood pressure, lipids, and cardiovascular risk factors. Small increase in systolic BP (1-1.5 mmHg) may occur with MHT.
Annual Reassessment
Yearly evaluation of continued need for therapy, symptom status, side effects, and any changes in risk factors or contraindications.
Reference: Treatment of menopausal symptoms with hormone therapy. UpToDate 2024
Compounded Hormones
Compounded Bioidentical Hormone Therapy: Not Recommended
We suggest AGAINST the use of custom-compounded bioidentical hormone therapy. There is no evidence for their safety or efficacy when compared with approved and commercially available products for MHT.
Lack of Regulatory Oversight
Contents, dose, quality, and sterility of compounded products are not subject to FDA regulatory oversight. When tested, potencies ranged from 67.5% to 268% of labeled amount.
No Safety or Efficacy Data
There are no randomized trials demonstrating either efficacy or safety of compounded bioidentical hormone therapy for treating menopausal symptoms.
Misleading Marketing
Often marketed as "natural" and "safer" than FDA-approved products, but this is not supported by evidence. Most FDA-approved estrogens are also plant-derived and bioidentical.
Expert groups including The Menopause Society, ACOG, and the Endocrine Society have issued scientific statements advising against the use of custom-compounded hormones.
There are numerous approved estrogen and progestin formulations available in all countries for MHT; therefore, there is no rationale for use of non-approved products.
Reference: Santoro N, et al. J Clin Endocrinol Metab 2016;101:1318; ACOG Committee Opinion #322, 2005
Key Differences: Approved vs Compounded Hormones
The chart illustrates relative scores (0-100) comparing FDA-approved hormones to compounded preparations across key quality and safety parameters.
FDA-Approved Products
Rigorous quality control and testing
Proven efficacy in clinical trials
Established safety profiles
Consistent dosing and potency
Required package inserts with warnings
Post-market surveillance
Compounded Products
Variable quality control
No efficacy trials required
Limited safety data
Inconsistent potency (67-268% of label)
No standardized warnings
No systematic monitoring
Reference: Santoro N, et al. J Clin Endocrinol Metab 2016;101:1318
Guidelines
Summary of International Guidelines
The Menopause Society (2022)
MHT is the most effective treatment for vasomotor symptoms. For women <60 years or within 10 years of menopause without contraindications, benefits outweigh risks. Individualize therapy.
Endocrine Society (2015)
Recommend calculating cardiovascular and breast cancer risks before initiating MHT. Suggest transdermal estrogen for moderate CVD risk. Micronized progesterone preferred over synthetic progestins.
ACOG (2014, Reaffirmed 2018)
MHT is appropriate for women with bothersome vasomotor symptoms. Use lowest effective dose for shortest duration needed. Not recommended for chronic disease prevention.
USPSTF (2022)
Recommends against use of combined estrogen-progestin or estrogen alone for primary prevention of chronic conditions in postmenopausal women. Does not address symptom treatment.
All major guidelines emphasize individualized decision-making, shared decision-making with patients, and regular reassessment of the need for continued therapy.
Reference: The 2022 Hormone Therapy Position Statement. Menopause 2022;29:767; Stuenkel CA, et al. J Clin Endocrinol Metab 2015;100:3975
Clinical Pearls for Menopausal Management
Diagnosis
For women >45 years with irregular cycles and menopausal symptoms, no further testing needed. FSH testing not required and may be misleading due to variability.
Timing Matters
Initiating MHT within 10 years of menopause or before age 60 has the most favorable risk-benefit profile. Avoid starting after age 60.
Route Selection
Prefer transdermal over oral estrogen for lower VTE and stroke risk. Particularly important for women with cardiovascular risk factors.
Progestogen Choice
Micronized progesterone preferred over synthetic progestins. Better cardiovascular and breast cancer risk profile. Take at bedtime due to somnolence.
Start Low, Go Slow
Begin with low-dose estrogen and titrate up as needed. Lower doses have fewer side effects and similar efficacy for many women.
Individualize Duration
Standard recommendation is 3-5 years, but extended use may be appropriate for women with persistent symptoms and favorable risk profile.
Reference: The 2022 Hormone Therapy Position Statement. Menopause 2022;29:767
Future Directions
Emerging Research and Future Directions
Novel Therapies
Neurokinin 3 receptor antagonists (fezolinetant, elinzenetant)
Selective estrogen receptor modulators (SERMs)
Tissue-selective estrogen complexes (TSECs)
Novel progestogens with improved safety profiles
Research Priorities
Long-term safety of newer MHT regimens
Biomarkers for personalized therapy selection
Optimal duration and tapering strategies
Effects of different progestogens on breast cancer risk
Cardiovascular effects in diverse populations
Cognitive effects and dementia prevention
Precision Medicine Approach
Future research aims to identify genetic and clinical factors that predict individual response to MHT and risk of adverse events, enabling truly personalized therapy.
Health Disparities
More research needed on menopausal symptoms and MHT effects in diverse racial and ethnic populations, as most data come from predominantly white cohorts.
Reference: Simon JA, et al. Climacteric 2025;28:98
Addressing Common Patient Concerns
"Will I gain weight?"
Meta-analysis of 28 trials found no evidence that MHT causes weight gain. Women typically gain weight during midlife, but this is not due to menopausal status or MHT.
"What about breast cancer?"
For women ages 50-59 taking MHT for 5 years, absolute risk is very low: 3 additional cases per 1000 women with EPT. Unopposed estrogen may actually reduce risk.
"Is it safe for my heart?"
For healthy women <60 years or within 10 years of menopause, MHT does not increase cardiovascular risk and may be protective. Timing of initiation is key.
"How long can I take it?"
Standard recommendation is 3-5 years, but extended use may be appropriate if benefits outweigh risks. Regular reassessment is important.
Addressing patient concerns with evidence-based information is crucial for shared decision-making. Many fears about MHT are based on outdated or misinterpreted data from the WHI.
Reference: Manson JE, Kaunitz AM. N Engl J Med 2016;374:803
Impact of WHI on Clinical Practice
1
Pre-2002
25-30% of postmenopausal women used MHT. Widely prescribed for symptom relief and chronic disease prevention.
2
2002: WHI Published
Initial WHI results showed increased risks in older women. Media coverage created widespread fear of MHT.
3
2002-2010
Dramatic decline in MHT use. By 2010, only 6.9% of women used MHT. Many symptomatic women left untreated.
4
2010-Present
Reanalysis shows favorable risk-benefit in younger women. Current use only 3-4%. Need for improved education.
The WHI had profound impact on clinical practice, leading to an 80% decrease in MHT prescriptions. However, subsequent analyses showed that results in older women should not be extrapolated to younger, symptomatic women.
Despite abundant data demonstrating safety of MHT in younger postmenopausal women, prescription rates remain extremely low. This highlights the need for better education of clinicians and patients.
Reference: Sprague BL, et al. Obstet Gynecol 2012;120:595; Yang L, Toriola AT. JAMA Health Forum 2024;5:e243128
Education Gap
The Need for Improved Medical Education
Current State
Emerging data suggest that medical school graduates and residents in internal medicine, obstetrics/gynecology, and family medicine now receive little or no training in the management of menopausal women.
In one survey of residents during their final year of training:
30-50% felt "not at all" prepared to manage menopausal women
50-60% unable to identify optimal therapy for symptomatic 52-year-old woman
50-60% unable to recommend appropriate treatment for 39-year-old with POI
Urgent Need
These data highlight the urgent need for better education of students, residents, and junior faculty in menopausal medicine.
01
Medical School Curriculum
Integrate comprehensive menopause education into medical school curriculum
02
Residency Training
Ensure adequate training in menopause management during residency programs
03
Continuing Education
Provide ongoing CME opportunities for practicing clinicians
04
Specialty Certification
Encourage menopause specialty certification (NCMP) for interested clinicians
Reference: Kling JM, et al. Mayo Clin Proc 2019;94:242; Manson JE, Kaunitz AM. N Engl J Med 2016;374:803
Practical Algorithm for MHT Decision-Making
This algorithm provides a systematic approach to evaluating women for MHT candidacy. Key decision points include age, presence of contraindications, symptom severity, and individual risk assessment.
Remember that this is a guide, not a rigid protocol. Clinical judgment and shared decision-making with the patient are essential components of the decision-making process.
Reference: Stuenkel CA, et al. J Clin Endocrinol Metab 2015;100:3975
Case-Based Learning: Clinical Scenarios
1
Scenario 1: Typical Candidate
52-year-old woman, 2 years postmenopausal, severe hot flashes affecting sleep and work. No contraindications. BMI 24. Recommendation: Initiate low-dose transdermal estradiol with micronized progesterone.
2
Scenario 2: Cardiovascular Risk
56-year-old woman, 4 years postmenopausal, moderate hot flashes. Hypertension, high cholesterol, 10-year CVD risk 8%. Recommendation: Transdermal estradiol preferred over oral. Consider nonhormonal options.
3
Scenario 3: Early Menopause
42-year-old woman, irregular cycles, hot flashes. Labs show elevated FSH. Recommendation: Rule out other causes first. If early menopause confirmed, initiate MHT and continue until age 50-51.
4
Scenario 4: Breast Cancer History
58-year-old woman, 5 years post-breast cancer treatment, severe hot flashes. Recommendation: MHT contraindicated. Offer nonhormonal options: SSRI, gabapentin, or fezolinetant.
These scenarios illustrate the importance of individualized assessment and decision-making. Each patient requires careful evaluation of risks, benefits, and preferences.
Reference: Clinical practice guidelines and expert consensus
Key Takeaways
Summary: Essential Points for Clinical Practice
Diagnosis is Clinical
For women >45 years with irregular cycles and menopausal symptoms, diagnosis is clinical. FSH testing not required and may be misleading.
MHT is Safe for Appropriate Candidates
For healthy women <60 years or within 10 years of menopause with moderate-severe symptoms, benefits of MHT outweigh risks. Absolute risks are very low.
Prefer Transdermal Estrogen
Transdermal estradiol has lower VTE and stroke risk compared to oral estrogen. Particularly important for women with cardiovascular risk factors.
Choose Micronized Progesterone
Natural micronized progesterone preferred over synthetic progestins for better cardiovascular and breast cancer risk profile.
Individualize Therapy
Start low, titrate as needed. Duration should be individualized based on symptoms, risks, and patient preference. Regular reassessment essential.
Avoid Compounded Products
Do not recommend custom-compounded bioidentical hormones. Lack of quality control, safety data, and efficacy data.
Reference: The 2022 Hormone Therapy Position Statement. Menopause 2022;29:767
Resources for Clinicians and Patients
Professional Organizations
The Menopause Society (formerly NAMS) - Clinical guidelines, educational resources, NCMP certification
Endocrine Society - Clinical practice guidelines on MHT
ACOG - Committee opinions and practice bulletins
International Menopause Society - Global perspectives and guidelines
Patient Education Resources
The Menopause Society patient education materials
UpToDate patient education articles (Beyond the Basics)
ACOG patient FAQs
Evidence-based websites and apps
Clinical Guidelines
Access to current evidence-based guidelines from major professional societies for clinical decision support.
CME Opportunities
Continuing medical education courses, webinars, and conferences focused on menopause management.
Research Updates
Stay current with latest research through medical journals, systematic reviews, and meta-analyses.
Reference: The Menopause Society (www.menopause.org); Endocrine Society (www.endocrine.org)
Shared Decision-Making Framework
Effective management of menopausal symptoms requires a collaborative approach between clinician and patient. Shared decision-making ensures that treatment decisions align with patient values and preferences.
Discuss Options
Present all available treatment options including MHT, nonhormonal therapies, and lifestyle modifications
Review Risks & Benefits
Provide personalized risk-benefit information based on patient's age, medical history, and risk factors
Explore Values
Understand patient's values, preferences, concerns, and treatment goals
Make Decision Together
Collaborate to select treatment plan that aligns with patient's informed preferences
Monitor & Reassess
Regular follow-up to assess response, manage side effects, and reassess continued need
This cyclical process emphasizes ongoing communication and reassessment. Treatment decisions are not static but should be revisited regularly as circumstances change.
Reference: Shared decision-making in clinical practice. Best practice guidelines 2024
Quality of Life: The Ultimate Goal
Beyond Symptom Relief
While relief of vasomotor symptoms is the primary goal of MHT, the ultimate objective is to improve overall quality of life for menopausal women.
Quality of life encompasses:
Physical well-being
Emotional health
Social functioning
Work productivity
Sexual health
Sleep quality
Holistic Approach
Effective menopause management requires a holistic approach that addresses not only physical symptoms but also psychological, social, and sexual health concerns.
This may include combination of:
Hormone therapy when appropriate
Lifestyle modifications
Mental health support
Sexual health counseling
94%
Sleep Interference
Women with severe symptoms report sleep interference
85%
Mood Impact
Report interference with mood
84%
Concentration
Report difficulty with concentration
—
Reference: Williams RE, et al. Maturitas 2009;62:153
Conclusion
Conclusions and Future Perspectives
Menopause is a natural transition that affects all women, with significant impact on quality of life for many. Evidence-based management of menopausal symptoms has evolved substantially over the past two decades.
Evidence-Based Care
Current evidence supports safe use of MHT in appropriate candidates
Individualized Approach
Treatment must be tailored to each woman's unique circumstances
Education Needed
Improved education for clinicians and patients is essential
Ongoing Research
Continued research to optimize safety and efficacy
Improved Access
Ensure all women have access to evidence-based care
The future of menopause management lies in precision medicine approaches, novel therapies, and improved education. By applying current evidence and individualizing care, we can significantly improve the lives of menopausal women.
Reference: Simon JA, et al. Climacteric 2025;28:98; The 2022 Hormone Therapy Position Statement. Menopause 2022;29:767
Key References and Further Reading
Landmark Studies
Harlow SD, et al. STRAW+10 staging system. J Clin Endocrinol Metab 2012;97:1159
Rossouw JE, et al. WHI combined EPT trial. JAMA 2002;288:321
Anderson GL, et al. WHI estrogen-alone trial. JAMA 2004;291:1701
Manson JE, et al. WHI 13-year follow-up. JAMA 2013;310:1353
Manson JE, et al. WHI 18-year follow-up. JAMA 2017;318:927
Clinical Guidelines
The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause 2022;29:767
Stuenkel CA, et al. Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2015;100:3975
ACOG Practice Bulletin No. 141. Obstet Gynecol 2014;123:202
Simon JA, et al. IMS World Congress 2024. Climacteric 2025;28:98
Systematic Reviews
Marjoribanks J, et al. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2017;1:CD004143
Cardiovascular Studies
Canonico M, et al. Hormone replacement therapy and risk of venous thromboembolism. BMJ 2008;336:1227
Renoux C, et al. Transdermal and oral HRT and stroke risk. BMJ 2010;340:c2519
Acknowledgments: This presentation is based on international clinical practice guidelines and systematic reviews of the evidence. All recommendations reflect current best practices in evidence-based medicine.
For complete reference list and additional resources, please refer to UpToDate, The Menopause Society, and Endocrine Society websites.
Professor Mykhailo Medvediev
Based on: Harlow SD, et al. J Clin Endocrinol Metab 2012;97:1159; The 2022 Hormone Therapy Position Statement. Menopause 2022;29:767; Stuenkel CA, et al. J Clin Endocrinol Metab 2015;100:3975; and other international evidence-based guidelines